VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH AL 2020 | Treatment options for Ph+ ALL

Oliver Ottmann, MD, FRCPath, University of Cardiff, Cardiff, UK, discusses the efficacy and drawbacks of tyrosine kinase inhibitors (TKIs) as a potential treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter